Recently Viewed

  • Home
  • Stories
  • News Announcement
  • Natco Pharma: NATCO's marketing partner Mylan Invalidates Two of Teva's Copaxone 40 mg/mL Patents Via U.S. Patent and Trademark Office's Inter Partes Review Proceeding
News Announcement

Natco Pharma: NATCO's marketing partner Mylan Invalidates Two of Teva's Copaxone 40 mg/mL Patents Via U.S. Patent and Trademark Office's Inter Partes Review Proceeding

25-Aug-2016 Follow Value Research Online on Google Natco Pharma

Natco Pharma Ltd has submitted to BSE a copy of Press Release dated August 25, 2016 titled NATCOs marketing partner Mylan Invalidates Two of Tevas Copaxone 40 mg/mL Patents Via U.S. Patent and Trademark Offices Inter Partes Review Proceeding'.

Ask Value Research aks value research information

No question is too small. Share your queries on personal finance, mutual funds, or stocks and let us simplify things for you.